Concepedia

Bilal Hameed

BH

Statistics

Publications

58

Citations

11.1K

H-Index

39

Active since

2005

Affiliations

University of California, San Francisco(Current)

Virginia Commonwealth University

University of California San Diego

The University of Texas Southwestern Medical Center

Duke University

Bilal Hameed is an author at University of California, San Francisco specializing in medicine, liver disease, and hepatology.

ORCID

Publications per year

2005–2024

58

Publications

58

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal et al. · The Lancet · 2014 · 2.2K citations

, , +14

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

, , +8

Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease

Arun J. Sanyal, Mark L. Van Natta, Jeanne M. Clark et al. · New England Journal of Medicine · 2021 · 1.1K citations · Full text

, , +12

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi et al. · The Lancet · 2021 · 564 citations · Full text

, , +6

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2021 · 521 citations · Full text

, , +11

1–5 of 58